Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
Vaxcyte (NasdaqGS:PCVX) has completed a major public equity offering, adding fresh capital to its balance sheet. The company is advancing its 31 valent pneumococcal conjugate vaccine candidate, VAX-31, into multiple Phase 3 trials in adults and infants. The funding event and clinical progress come at the same time and are material for Vaxcyte's development plans in pneumococcal disease. Vaxcyte focuses on vaccines targeting pneumococcal disease, an area where prevention remains a key public health priority. By moving VAX-31 into late stage studies across both adult and infant populations, the company is positioning itself within a segment that often attracts long term attention from healthcare systems and policymakers. For investors, the combination of new equity capital and advancing clinical trials creates a period in which regulatory, clinical and partnership milestones could play an important role. The outcome and timing of these steps are uncertain, and they are likely t
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in AdultsGlobeNewswire
- Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) CandidateGlobeNewswire
- Vaxcyte (PCVX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte's VAX-31 Shift the Bull Case (PCVX)? [Yahoo! Finance]Yahoo! Finance
PCVX
Earnings
- 2/24/26 - Miss
PCVX
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/18/26 - Form 4
- 3/17/26 - Form 144
- PCVX's page on the SEC website